EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fibroblast Growth Factor 23, Glucose Homeostasis, and Incident Diabetes: Findings of 2 Cohort Studies

Amarens van der Vaart iD, Coby Eelderink iD, André P van Beek, Stephan J L Bakker, Peter R van Dijk, Martin H de Borst

The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · e971-e978

DOI: 10.1210/clinem/dgad246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 04.05.2023. Verfasst von Amarens van der Vaart und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, 9700 RB, Groningen, the Nether…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Fibroblast Growth Factor-23. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public-Private Partnership TKI Agri & Food, Dutch dairy company Friesland Campina, University Medical Center Groningen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The phosphate-regulating hormone fibroblast growth factor 23 (FGF23) has been linked to deregulations in glucose metabolism, but its role is insufficiently understood.

Objective

This study investigates potential crosstalk between FGF23 and glucose homeostasis.

Methods

First, we investigated the effect of glucose loading on plasma C-terminal FGF23 levels and its temporal relationship with changes in plasma phosphate in 45 overweight (body mass index [BMI] 25-30) individuals using time-lag analyses. Second, we studied cross-sectional associations of plasma C-terminal FGF23 levels with glucose homeostasis using multivariable linear regression in a population-based cohort. We also investigated associations of FGF23 with incident diabetes and obesity (BMI > 30) in individuals without diabetes or obesity at baseline, respectively, using multivariable Cox regression analyses. Finally, we explored whether the association between FGF23 and diabetes depends on BMI.

Results

After glucose loading, changes in FGF23 preceded changes in plasma phosphate (Ptime-lag = .04). In the population-based cohort (N = 5482; mean age 52 years, 52% women, median FGF23 69 RU/mL), FGF23 was associated with plasma glucose (β = .13 [.03-.23]; P = .01), insulin (β = .10 [.03-.17]; P < .001), and proinsulin (β = .06 [0.02-0.10]; P = .01) at baseline. On longitudinal analyses, a higher baseline FGF23 was independently associated with development of diabetes (199 events [4%]; fully adjusted hazard ratio [HR] 1.66 [95% CI, 1.06-2.60]; P = .03) and development of obesity (241 events [6%]; fully adjusted HR 1.84 [95% CI, 1.34-2.50]; P < .001). The association between FGF23 and incident diabetes lost significance after additional adjustment for BMI.

Conclusion

Glucose loading has phosphate-independent effects on FGF23 and, vice versa, FGF23 is associated with glucose, insulin and proinsulin levels, and obesity. These findings suggest crosstalk between FGF23 and glucose homeostasis, which may promote susceptibility to incident diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusFibroblast Growth Factor-23FemaleHumansMaleMiddle AgedCohort StudiesCross-Sectional StudiesFibroblast Growth FactorsGlucoseHomeostasisObesityPhosphatesProinsulin

Stichwörter der Autor:innen

fibroblast growth factor 23glucose loadingtype 2 diabetes

Substanzen

Fibroblast Growth Factor-23Fibroblast Growth FactorsGlucosePhosphatesProinsulinFGF23 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, 9700 RB, Groningen, the Netherlands.
  • Department of Endocrinology, University Medical Center Groningen, University of Groningen, 9700 RB, Groningen, the Netherlands.

ORCID-Profile: Amarens van der Vaart, Coby Eelderink

Förderung

  • Public-Private Partnership TKI Agri & Food
  • Dutch dairy company Friesland Campina
  • University Medical Center Groningen

Zitieren

APA

van der Vaart, A., Eelderink, C., van Beek, A. P., Bakker, S. J. L., van Dijk, P. R., & de Borst, M. H. (2023). Fibroblast Growth Factor 23, Glucose Homeostasis, and Incident Diabetes: Findings of 2 Cohort Studies. The Journal of Clinical Endocrinology & Metabolism, 108(10), e971-e978. https://doi.org/10.1210/clinem/dgad246

Vancouver

van der Vaart A, Eelderink C, van Beek AP, Bakker SJL, van Dijk PR, de Borst MH. Fibroblast Growth Factor 23, Glucose Homeostasis, and Incident Diabetes: Findings of 2 Cohort Studies. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):e971-e978. doi:10.1210/clinem/dgad246

BibTeX
@article{vanderVaart2023,
  author = {van der Vaart, Amarens and Eelderink, Coby and van Beek, André P and Bakker, Stephan J L and van Dijk, Peter R and de Borst, Martin H},
  title = {Fibroblast Growth Factor 23, Glucose Homeostasis, and Incident Diabetes: Findings of 2 Cohort Studies},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {10},
  pages = {e971--e978},
  doi = {10.1210/clinem/dgad246}
}
Kostenlos starten →